Hostname: page-component-76fb5796d-x4r87 Total loading time: 0 Render date: 2024-04-26T07:32:43.935Z Has data issue: false hasContentIssue false
  • English
  • Français

Intradermal Recombinant Hepatitis B Vaccine for Healthcare Workers Who Fail to Respond to Intramuscular Vaccine

Published online by Cambridge University Press:  02 January 2015

E. Geoffrey Playford ,
Patrick G. Hogan ,
Amolak S. Bansal ,
Kareena Harrison ,
David Drummond ,
David F. M. Looke  and
Michael Whitby
E. Geoffrey Playford*
Affiliation:
Infection Management Service, Princess Alexandra Hospital and District Health Service, Brisbane, Queensland, Australia
Patrick G. Hogan
Affiliation:
Department of Immunology, Princess Alexandra Hospital and District Health Service, Brisbane, Queensland, Australia
Amolak S. Bansal
Affiliation:
Department of Immunology, Princess Alexandra Hospital and District Health Service, Brisbane, Queensland, Australia
Kareena Harrison
Affiliation:
Infection Management Service, Princess Alexandra Hospital and District Health Service, Brisbane, Queensland, Australia
David Drummond
Affiliation:
Queensland Medical Laboratories, Brisbane, Queensland, Australia
David F. M. Looke
Affiliation:
Infection Management Service, Princess Alexandra Hospital and District Health Service, Brisbane, Queensland, Australia
Michael Whitby
Affiliation:
Infection Management Service, Princess Alexandra Hospital and District Health Service, Brisbane, Queensland, Australia
*
Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, NSW 2145, Australia
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To study the humoral immune responses, safety, and tolerability of intradermal recombinant hepatitis B vaccination in healthcare workers (HCWs) nonresponsive to previous repeated intramuscular vaccination.

Design:

An open, prospective, before–after trial.

Setting:

A tertiary referral hospital and surrounding district health service in Queensland, Australia.

Participants:

Hospital and community HCWs nonresponsive to previous intramuscular hepatitis B vaccination.

Methods:

Intradermal recombinant hepatitis B vaccine was administered every second week for a maximum of 4 doses. Hepatitis B surface antibody (anti-HBs) responses were assessed 2 weeks after each dose.

Results:

Protective anti-HBs levels developed in 17 (94%) of 18 study subjects. Three doses resulted in seroconversion of all responding subjects and the highest geometric mean antibody concentration. The vaccine was well tolerated.

Conclusion:

More than 90% of previously nonresponsive HCWs responded to intradermal recombinant hepatitis B vaccine with protective anti-HBs levels.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 23 , Issue 2 , February 2002 , pp. 87 - 90
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Centers for Disease Control and Prevention. Immunization of healthcare workers: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Advisory Committee (HICPAC). MMWR 1997;46(RR-18):1–42.Google Scholar
2.National Health and Medical Research Council. The Australian Immunisation Handbook, 6th ed. Canberra, Australia: Australian Government Publishing Service; 1997.Google Scholar
3.Roome, AJ, Walsh, SJ, Cartter, ML, Hadler, JL. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA 1993;270:2931–2934.Google Scholar
4.Wood, RC, MacDonald, KL, White, KE, Hedberg, CW, Hanson, M, Osterholm, MT. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 1993;270:2935–2939.CrossRefGoogle ScholarPubMed
5.Szmuness, W, Stevens, CE, Harley, EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980;303:833–841.CrossRefGoogle Scholar
6.Stevens, CE, Alter, HJ, Taylor, PE, et al. Hepatitis B vaccine in patients receiving hemodialysis: immunogenicity and efficacy. N Engl J Med 1984;311:496–501.CrossRefGoogle ScholarPubMed
7.Lindsay, KL, Herbert, DA, Gitnick, GL. Hepatitis B vaccine: low post-vaccination immunity in hospital personnel given gluteal injections. Hepatology 1985;5:1088–1090.Google Scholar
8.Alper, CA, Kruskall, MS, Marcus-Bagley, D, et al. Genetic predisposition of nonresponse to hepatitis B vaccine. N Engl J Med 1989;321:708–712.CrossRefGoogle Scholar
9.Weissman, JY, Tsuchiyose, MM, Tong, MJ, et al. Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine. JAMA 1988;260:1734–1738.Google Scholar
10.Struve, J, Aronsson, B, Frenning, B, et al. Seroconversion after additional vaccine doses to non-responders to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccine. Scand J Infect Dis 1994;26:468–470.CrossRefGoogle ScholarPubMed
11.Levitz, RE, Cooper, BW, Regan, HC. Immunization with high dose intradermal recombinant hepatitis B vaccine in healthcare workers who fail to respond to intramuscular vaccination. Infect Control Hosp Epidemiol 1995;16:88–91.Google Scholar
12.Lutwick, LI. The development and duration of an antibody response to intradermal hepatitis B virus vaccination in poor responders to intramuscular route: a five year follow-up. Presented at the Annual Meeting of the Society for Hospital Epidemiology of America; April 18-20, 1999; San Francisco, CA. Abstract.Google Scholar
13.Nagafuchi, S, Kashiwagi, S, Okada, K, et al. Reversal of nonresponders and postexposure prophylaxis by intradermal hepatitis B vaccination in Japanese medical personnel. JAMA 1991;265:2679–2683.CrossRefGoogle ScholarPubMed
14.Tsuyi, K, Aizawa, M, Sasazuki, T, eds. HLA 1991: Proceedings of the 11th International Histocompatibility Workshop and Conference, vol. 1. Oxford, UK: Oxford University Press; 1992:1065–1220.Google Scholar
15.Centers for Disease Control and Prevention. Epidemiologic notes and reports: inadequate immune response among public safety workers receiving intradermal vaccination against hepatitis B—United States, 1990-1991. MMWR 1991;40:569–572.Google Scholar
16.West, DJ, Calandra, GB. Vaccine induced immunological memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1996;14:1019–1027.Google Scholar
17.Assad, S, Francis, A. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine 1999;18:57–67.Google Scholar
18.Bryan, JP, Sjogren, MH, Perine, PL, Legters, LJ. Low-dose intradermal and intramuscular vaccination against hepatitis B. Clin Infect Dis 1992;14:697–707.Google Scholar
19.Frazer, IH, Jones, B, Dimitrakakis, M, Mackay, IR. Intramuscular versus low-dose hepatitis B vaccine. Med J Aust 1987;146:242–245.Google Scholar
20.Platt, J, Grant, B, Eddy, A, Michael, A. Immune cell properties in cutaneous delayed-type hypersensitivity. J Exp Med 1983;158:1227–1242.CrossRefGoogle Scholar
21.Unanue, ER. Macrophages, antigen-presenting cells, and the phenomena of antigen handling and presentation. In: Paul, WE, ed. Fundamental Immunology. New York: Raven Press; 1989:95–115.Google Scholar
22.Fabrizi, F, Andrulli, S, Bacchini, G, Corti, M, Locatelli, F. Intradermal versus intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. Nephrol Dial Transplant 1997;12:1204–1211.Google Scholar